Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival

Tadeu Ferreira Paiva Jr.1, Victor Hugo Fonseca de Jesus1, Raul Amorim Marques1, Alexandre André Baleiro Anastácio da Costa1, Mariana Petaccia de Macedo2, Patricia Maria Peresi2, Aline Damascena3, Benedito Mauro Rossi4, Maria Dirlei Begnami2 and Vladmir Cláudio Cordeiro de Lima1,5*

Abstract

Background: The development of targeted therapies has undoubtedly broadened therapeutic options for patients with colorectal cancer (CRC). The use of bevacizumab to reduce angiogenesis has been associated with improved clinical outcomes. However, an urgent need for prognostic/predictive biomarkers for anti-angiogenic therapies still exists.

Methods: Clinical data of 105 CRC patients treated with bevacizumab in conjunction with chemotherapy were analyzed. The expression of vascular endothelial growth factor (VEGF) receptors, NOTCH1 receptor and its ligand DLL4 were determined by immunohistochemistry. Tumor samples were arranged on a tissue microarray. The association between protein expression and clinicopathological characteristics and outcomes was determined.

Results: Bevacizumab was administered as a first-line of treatment in 70.5% of our cases. The median progression-free survival (PFS) was 10.2 months. The median overall survival (OS) of the total cohort was 24.4 months. Bevacizumab, as the first-line of treatment, and the presence of liver metastasis were independently associated with objective response rate. Membrane VEGFR1 and VEGFR3 expressions were associated with the presence of lung metastasis; interestingly, VEGFR3 was associated with less liver metastasis. NOTCH1 expression was associated with lymph node metastasis. There was a trend toward association between improved PFS and lower NOTCH1 expression (p = 0.06). Improved OS was significantly associated with lower NOTCH1 expression (p = 0.01). In a multivariate analysis, ECOG (Eastern Cooperative Oncology Group) performance status, liver metastasis, histological grade, and NOTCH1 expression were independently associated with OS.

Conclusion: Our findings illustrated the expression profile of angiogenesis-related proteins and their association with clinicopathological characteristics and outcomes. NOTCH1 expression is a detrimental prognostic factor in metastatic CRC patients treated with chemotherapy plus bevacizumab.

Keywords: Colorectal cancer, Angiogenesis, NOTCH1, Survival

* Correspondence: vladcclima@gmail.com
1Department of Medical Oncology, A. C. Camargo Cancer Center, São Paulo, Brazil
2Department of Clinical Oncology, 1st Subsolo, Edificio Hilda Jacob R. Prof. Antônio Prudente, 211, São Paulo ZC 01509-900, Brazil
Full list of author information is available at the end of the article
Background

Colorectal cancer (CRC) is the fourth most common cause of death worldwide, accounting for 694,000 deaths in 2012. CRC incidence is higher in men than in women, being the third most common cancer in men and the second in women [1]. Almost 50% of patients will develop metastases and ~25% already have metastasis at diagnosis [2]. Although CRC incidence and mortality rates vary markedly around the world, CRC is mainly a disease of developed Western countries. For 2015, it has been estimated that the United States will have 132,700 new cases of CRC and 49,700 related deaths [3]. In Brazil, 32,600 new cases of colorectal cancer were expected in 2014 (http://www.inca.gov.br/estimativa/2014/).

Angiogenesis induction is pivotal to tumor growth and metastases. From a molecular perspective, angiogenesis is triggered by hypoxia, cytokines, oncogenes activating mutations, growth factors and hormones that directly or indirectly promote the production and release of an array of proteins genetically and functionally related to VEGFA (vascular endothelial growth factor A). Subsequently, these proteins bind to and activate specific membrane tyrosine-kinase receptors (VRGFR1, VEGFR2 and VEGFR3) [4].

Similarly, a family of membrane bound receptors related to the protein NOTCH (NOTCH1, NOTCH2, NOTCH3 and NOTCH4) interact with membrane bound ligands (JAGGED-1 or JAG1, JAG2, delta-like-1 or DLL1, DLL3 and DLL4) and act to regulate cell proliferation, differentiation and apoptosis, as well as angiogenesis and tumor cell migration [5, 6]. Some data suggest that VEGFR2 activation by VEGFA upregulates DLL4 in tip cells. DLL4 in turn binds to and activates NOTCH1 on stalk cells, reducing VEGFR2 expression and subsequently increasing VEGFR1, thus constituting a negative feedback for the activity of VEGFA [7].

In the last several years, the development of targeted therapies has provided therapeutic options for patients with metastatic CRC in addition to improved clinical outcomes. The median overall survival (OS) has increased by >12 months since the introduction of therapies using biological compounds and double/triplet chemotherapy regimens [8]. Bevacizumab (Avastin: Genentech, San Francisco, CA, USA), a monoclonal antibody, is a potent inhibitor of vascular endothelial growth factor (VEGF), and has been shown to reduce angiogenesis [9]. The efficacy and safety of bevacizumab have been demonstrated as both a first and second-line treatment [10–12]. In combination with chemotherapy, bevacizumab has been shown to improve the overall response rate (RR), median progression-free survival (PFS) and median OS [13]. The majority of previously untreated metastatic CRC patients are now treated with bevacizumab in combination with oxaliplatin and fluorouracil (FOLFOX) [14]. Furthermore, recent data have shown some clinical benefit in maintaining VEGF inhibition with bevacizumab beyond disease progression [15].

Although significant improvements in outcome rates have been reported with various anti-VEGF agents, a substantial number of patients do not obtain a pronounced benefit, which is most likely due to resistance mechanisms [16]. DLL4-induced Notch signaling, one of the mechanisms reported to mediate tumor resistance related to anti-VEGF therapy, activates multiple parallel pathways and induces the formation of large distorted vessels [7]. The Notch signaling pathway has emerged as an attractive target for angiogenesis-based cancer therapies [17]. However, despite the increasing role of various antiangiogenic drugs in personalized metastatic CRC care, no biomarkers have been identified capable of predicting response to antiangiogenic therapy. Several markers have been tested in preclinical models but failed as predictors of response in human trials [18]. Thus, there is an urgent need for prognostic/predictive biomarkers for anti-VEGF therapies.

In this retrospective study, clinical features and outcomes in a cohort of 105 CRC patients who received bevacizumab-containing regimens were reviewed and presented. The expression of VEGF receptors, NOTCH1 receptor and its ligand DLL4 in CRC tissues as well as the evaluation of their relationships with clinicopathological characteristics and outcomes were determined retrospectively. Importantly, the patient population was relatively homogeneous due to consistent eligibility criteria, treatment guidelines, and evaluation parameters.

Methods

Patients and study design

The medical data from CRC metastatic patients treated with a combination of bevacizumab and chemotherapy were retrospectively analyzed. All data from May 2006 to November 2009 were obtained from chemotherapy registries from A.C. Camargo Cancer Center - Fundação Antônio Prudente. A total of 151 patients were found. Paraffin blocks were available for 117 patients, but in 11 of them the data or material were not suitable for analysis, therefore, a total of 105 patients were eligible for further study (Fig. 1). The study was approved by the Ethics Committee of A.C. Camargo Cancer Center - Fundação Antônio Prudente (number 1134/08). The need of an informed consent was waived by Ethics Committee.

Demographic and clinical data were collected and included relevant medical history, disease stage, tumor pathology at the initial diagnosis, details of chemotherapy regimens used with bevacizumab, data concerning the primary surgery, and metastasectomy. Tumors were staged according to the 7th edition of the TNM classification of malignant tumors [19]. Data for the response criteria and survival outcomes were based on the chart
review. Response criteria were evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) [20]. Cases treated before the publication of RECIST v1.1 were classified accordingly based on data extracted from image reports. The PFS was defined as the time from the beginning of bevacizumab treatment until the first observation of disease progression. The OS was defined as the time from the beginning of bevacizumab treatment until the date of either the last contact alive or death from any cause. Hypertension was defined when blood pressure was either persistently elevated (>24 h) or repeated blood arterial pressure measurements were above 140 × 90 mmHg. The Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 was used to grade hypertension [21]. Blood pressure values recorded by physicians and nurses during screening consultations, pre-chemotherapy, and prior to initiation of the antihypertensive treatment were analyzed. Archival pathological specimens were collected, and the expression of the angiogenesis-related proteins was first verified by immunohistochemistry and then quantified.

Construction of tissue microarray blocks and immunohistochemistry analysis
Archival formalin-fixed, paraffin-embedded specimens were obtained from patients who received bevacizumab. The chosen samples were from primary tumor and/or metastatic tissue collected as close as possible to the start of bevacizumab treatment. The paraffin blocks underwent tissue microarray construction before immunostaining. In brief, a fresh section stained with hematoxylin and eosin was cut from each block. The representative tumor areas were carefully selected and marked. Using a tissue microarrayer (Beecher Instruments, Silver Spring, MD, USA), 1 mm cylindrical cores were removed from each donor paraffin block and transferred to premolded recipient paraffin blocks, in duplicates. Sections 5 μm in thickness were placed on glass slides. In the recipient block, cores were arrayed according to the defined x-y coordinate position. Normal placenta tissue cores were used as a position marker. Slides were then incubated with the primary antibodies according to the manufacturer’s protocol. The polyclonal antibodies used in this study were: PlGF (1:20, R&D systems, Minneapolis, MN, USA), VEGFR2 (1:50, Neomarkers, Freemont, CA, USA), VEGFR3 (1:400, LabVision, Freemont, CA, USA), and DLL4 (1:200, Abcam, Cambridge, UK). The monoclonal antibodies used were VEGFR1 (1:50, clone Y103, Abcam, Cambridge, UK) and NOTCH1 (1:50, Thermo Scientific, clone A6, Rockford, IL, USA). Antibody detection was performed using a streptavidin-biotin system (Biotinylated Link Universal, LSAB+, Carpinteria, CA, USA) for PlGF and a biotin-free polymeric visualization system (Novolink Max Polymer, Carpinteria, CA, USA) for all the other antibodies, according to the manufacturer’s protocol. Glass slides were digitalized using the Aperio Scan-Scope XT Slide Scanner (Aperio Technologies, Vista, CA, USA) at 20x magnification. All the tumoral areas in the tissue microarray (spots) were evaluated and scored independently by the pathologist (M.M.P) and the oncologist (T.F.P.J.), without previous knowledge of the clinicopathological outcomes of the patients. The evaluation of the immunostaining was as follows: VEGFR1 (membrane and cytoplasm), VEGFR2 (membrane and cytoplasm), VEGFR3 (membrane and cytoplasm), PlGF in the cytoplasm, and DLL4 and NOTCH1 in the membrane. A membrane staining algorithm (Membrane v1, Aperio, Vista, CA, USA) was used to determine the intensity and extent of cell membrane staining. Tumor cells with weak or partial membrane staining were scored 1+; tumor cells with moderate and complete membrane staining were considered 2+; tumor cells with intense and complete membrane staining were classified as 3+. For each TMA core, the percentage of cells with score 0, +1, +2, +3 was registered. A positive staining was considered for cells with scores 2+ and 3+, except for DLL4, where a score of 1+, 2+ and 3+ were considered positive. The percentage of cells with positive staining in each TMA core was summed up. The mean value per replicate was used for the statistical analysis. A sample was considered non-representative when there were <500 analyzed cells. For the quantification of stain in the cytoplasm, the Positive Pixel Count Algorithm (Aperio, Vista, CA, USA) was used to sum the strongly and moderately positive pixels in each core. The analyses included the classification of staining as strongly, moderately and weakly positive, the number of negative cells, the analyzed area, and the ratio of the number of positive/total number of cells. The mean value per replicate was used for statistical analyses. A sample
was considered non-representative when there was an area <0.08 μm² (10 % of the total core area).

**Statistical analysis**

Descriptive statistics was used for the analysis of demographic and clinical characteristics. Frequencies and percentages were used for nominal/ordinal variables, while median and range were used for continuous variables. The response rates associated with demographic and clinical data were analyzed with the Chi-square and Fisher’s exact tests. Logistic regression was used to test the independent effect of some variables on the objective response rate; all variables with \( p \leq 0.05 \) were included in association tests. Correlations among angiogenesis-related proteins employed a Pearson’s correlation test. The survival curves were estimated using the Kaplan-Meier method and were compared using the log-rank test. Patients who were lost to follow-up were censored at the last contact date. Ordinal or nominal variables were dichotomized by grouping. To analyze the association of OS and PFS with angiogenesis-related protein expression, patients were subdivided into high or low-expression groups based on the median cut-off values. The Cox multivariate regression model was used to test for independent significance of clinical and pathological parameters on the OS.

All analyses were performed either with the R statistical software, version 2.3.0 (www.r-project.org) or SPPS v.17 statistical package (Chicago, IL, USA).

**Results**

**Patient and tumor characteristics**

Median age at diagnosis was 56 years (range, 28–80 years); 58 % of patients were male, and 51 % of patients presented one or more comorbidities. The most common CRC localization was descending/sigmoid colon. Although all tumors were adenocarcinomas, 9.6 % presented mucinous histology (mucinous and mucin-secreting) and 82.6 % were moderately differentiated. By the time of diagnosis, 72.8 % of patients had stage IV (synchronous metastases), the remaining patients developed metachronous metastases (27.2 %), the liver being the most common site of metastasis. Ninety-five percent of patients underwent resection of the primary tumor, and 58 % underwent metastasis resection at some point. Tumor characteristics are presented in Table 1.

Although most of the patients had an advanced stage of the disease at diagnosis, 96.9 % presented an ECOG (Eastern Cooperative Oncology Group) performance status of either 0 or 1. Bevacizumab was administered as the first, second, third, and even the fourth line of therapy, with the majority of cases (70 %) using it as the first-line. Irinotecan plus 5-fluorouracil and leucovorin was the most common chemotherapy drug regimen associated with bevacizumab (53.3 %). Hypertension is a common side effect of bevacizumab therapy. In our cohort, 25.8 % of patients experienced chemotherapy-related hypertension grade 2 or 3.

**Clinical outcomes**

In the total cohort of 105 patients, the median PFS was 10.2 months. There was a significant association between PFS and ECOG 0 or 1 (\( p = 0.002 \)), and PFS and histological differentiation grades 1+ and 2+ (\( p = 0.027 \)), shown in Fig. 2a and b. Concerning the presence of metastasis, a longer PFS was significantly associated with the presence of liver metastasis (\( p = 0.003 \), Fig. 2c), absence of lymph node metastasis (\( p = 0.014 \), Fig. 2d), absence of peritoneal metastasis (\( p = 0.023 \), Fig. 2e), and with patients undergoing metastasis resection (\( p < 0.001 \), Fig. 2f).

The median OS of the total cohort was 24.4 months (Fig. 3a). There was a significant association between better OS and ECOG 0 or 1 (\( p = 0.01 \), Fig. 3b). Improved OS was also associated with histological differentiation grades 1+ or 2+ (\( p = 0.006 \), Fig. 3c), presence of liver metastasis (\( p < 0.001 \), Fig. 3d), absence of lymph node metastasis (\( p = 0.004 \), Fig. 3e), and with patients undergoing metastasis resection (\( p < 0.0001 \), Fig. 3f). Patients who underwent metastasis resection at some point in the course of their disease had better OS (5-year survival rate of 40 %) as well as better PFS, with a10-year survival rate of 18 %.

Response rates were analyzed in 95 patients since nine patients did not present detectable disease prior to bevacizumab treatment and one patient had no data regarding response to treatment. Association with clinical variables is shown in Table 2. Histological differentiation grades 1+ and 2+, non-mucinous histology, liver metastasis and first-line therapy were significantly associated with better objective response rates. In a multivariate logistic regression model for objective response the included variables were line of bevacizumab treatment (first vs. others), combined histology (mucin-secreting vs. non-mucin-secreting), histological differentiation grade (1, 2 vs. 3) and the presence of liver metastasis (yes vs. no). Bevacizumab, used in the first-line of treatment, and the presence of liver metastasis were independently associated with objective response rate (Table 3).

We also evaluated ORR, PFS and OS from patients that received bevacizumab as a first-line (\( N = 73 \)) and second-line treatment (\( N = 29 \)) separately. Demographics and clinical characteristics of patients treated with bevacizumab as a first-line therapy are shown in (Additional file 1: Table S1). ORR, median PFS and median OS was 59.7 %, 10.6 months and 28.9 months in first-line and 36.0 %, 8.2 months and 19.9 months in second-line, respectively (Additional file 1: Table S2).

Angiogenesis-related proteins were investigated by immunohistochemistry in patients with the disease detected prior to bevacizumab treatment (Additional file 2: Figure S1).
The proteins expressed most abundantly were VEGFR1 and NOTCH1. The expression values for VEGFRs, PlGF, DLL4 and NOTCH1 are presented in Table 4. All of the VEGF receptors 1, 2 and 3 had significant positive correlations among each other for both membrane and cytoplasmic expression. All other significant correlations involving PlGF, DLL4 and NOTCH1 are presented in Table 5.

The clinical characteristics significantly associated with angiogenesis-related proteins are described in Table 6. DLL4 did not show any significant association with clinical characteristics. There was no significant association between objective response rate and the angiogenesis-related proteins investigated.

There was a trend toward an association between better PFS with lower NOTCH1 expression ($p = 0.06$, Fig. 4a). Better OS was significantly associated with lower NOTCH1 expression ($p = 0.01$, Fig. 4b). To determine the variables independently associated with OS, ECOG (0, 1 vs. 2, 3), metastasis resection (yes vs. no), lymph node metastasis (yes vs. no), peritoneal metastasis (yes vs. no), liver metastasis (yes vs. no), histological grade (1, 2 vs. 3), and NOTCH1 expression (lower vs. higher) were included in a multivariate analysis shown in Table 7.

**Discussion**

This retrospective analysis reports on the efficacy of bevacizumab administered across multiple lines of treatment in a large cohort of patients from a reference center in Brazil. We report the expression profile of angiogenesis-related proteins and their association with clinical characteristics and outcomes.

Several phase III clinical trials have confirmed the efficacy of bevacizumab in combination with FOLFOX or FOLFIRI in the first-line treatment for metastatic CRC [10, 22]. In 100 patients receiving, as the first-line therapy, bevacizumab with irinotecan, 5-fluorouracil and leucovorin, a median PFS of 8.8 months was reported compared to 6.8 months in the group without bevacizumab [10].

---

**Table 1** Tumor characteristics

| Characteristics                              | Frequency |
|----------------------------------------------|-----------|
| Localization ($n = 104$)                     |           |
| Descending/sigmoid colon                     | 57.7 %    |
| Medium and lower rectum                      | 22.1 %    |
| Ascending colon                              | 17.3 %    |
| Transverse colon                             | 2.9 %     |
| Histology ($n = 104$)                        |           |
| Adenocarcinoma NOS                           | 50.0 %    |
| Tubular adenocarcinoma                       | 39.4 %    |
| Mucin-secreting adenocarcinoma               | 4.8 %     |
| Mucinous adenocarcinoma                      | 3.8 %     |
| Signet ring cell carcinoma                   | 1.0 %     |
| Cribriform adenocarcinoma                    | 1.0 %     |
| Histologic differentiation ($n = 92$)        |           |
| Well (1)                                     | 6.5 %     |
| Moderate (2)                                 | 82.6 %    |
| Poor (3)                                     | 10.9 %    |
| Blood vessel invasion ($n = 81$)             |           |
| Yes                                          | 16.0 %    |
| No                                           | 84 %      |
| Lymphatic invasion ($n = 80$)                |           |
| Yes                                          | 36.3 %    |
| No                                           | 63.7 %    |
| Perineural invasion ($n = 78$)               |           |
| Yes                                          | 30.8 %    |
| No                                           | 69.2 %    |
| Depth of tumor invasion ($n = 98$)           |           |
| T1                                           | 2.0 %     |
| T2                                           | 6.1 %     |
| T3                                           | 75.5 %    |
| T4                                           | 15.3 %    |
| Tx                                           | 1.0 %     |
| Lymph node metastasis ($n = 98$)             |           |
| N0                                           | 30.6 %    |
| N1                                           | 32.7 %    |
| N2                                           | 35.7 %    |
| Nx                                           | 1.0 %     |
| Metastasis (M1) at diagnosis ($n = 104$)     |           |
| Yes                                          | 72.8 %    |
| No                                           | 27.2 %    |
| TNM staging at diagnosis ($n = 103$)         |           |
| I                                            | 1.0 %     |
| II                                           | 11.7 %    |
| III                                          | 14.6 %    |
| IV                                           | 72.8 %    |

---

**Table 1** Tumor characteristics (Continued)

| Metastatic sites ($n = 105$)     |            |
|----------------------------------|-------------|
| Liver                            | 65.7 %      |
| Lymph nodes                      | 25.7 %      |
| Lung                             | 33.3 %      |
| Peritoneum                       | 17.1 %      |
| Skin/subcutaneous                | 1.0 %       |
| Locoregional recidive            | 11.5 %      |
| Metastasis resection ($n = 105$) |            |
| Yes                              | 58.1 %      |
| No                               | 41.9 %      |

$n$: number of patients with available data in each category. Tumors were staged according to the 7th Edition of the TNM Classification of Malignant Tumors. NOS: not otherwise specified.

The proteins expressed most abundantly were VEGFR1 and NOTCH1. The expression values for VEGFRs, PlGF, DLL4 and NOTCH1 are presented in Table 4. All of the VEGF receptors 1, 2 and 3 had significant positive correlations among each other for both membrane and cytoplasmic expression. All other significant correlations involving PlGF, DLL4 and NOTCH1 are presented in Table 5.

The clinical characteristics significantly associated with angiogenesis-related proteins are described in Table 6. DLL4 did not show any significant association with clinical characteristics. There was no significant association between objective response rate and the angiogenesis-related proteins investigated.

There was a trend toward an association between better PFS with lower NOTCH1 expression ($p = 0.06$, Fig. 4a). Better OS was significantly associated with lower NOTCH1 expression ($p = 0.01$, Fig. 4b). To determine the variables independently associated with OS, ECOG (0, 1 vs. 2, 3), metastasis resection (yes vs. no), lymph node metastasis (yes vs. no), peritoneal metastasis (yes vs. no), liver metastasis (yes vs. no), histological grade (1, 2 vs. 3), and NOTCH1 expression (lower vs. higher) were included in a multivariate analysis shown in Table 7.
Reported PFS in this setting varied from 7 to 11 months [11, 22, 23]. In our cohort of 105 patients, 70.0% received bevacizumab in the first-line treatment with the median PFS of 10.6 months. Although this cohort included a high proportion of patients with advanced disease, our results are in line with reported data confirming the clinical value of bevacizumab. As to be expected, a significantly better PFS was associated with ECOG 0 or 1 and histological differentiation grades 1+ and 2+. Additionally, a better PFS was significantly associated with the absence of extrahepatic metastasis and the presence of liver metastasis, an outcome probably related to the high rate of metastasis resection (58.1%). Our data showed a median OS of 24.4 months, in line with the literature and associated with
similar factors that were also related to a better PFS, such as liver metastasis and metastasis resection [12, 22, 24, 25]. Concerning objective responses, better response rates were seen in histological differentiation grades 1+ and 2+, non-mucinous histology, liver metastasis, and bevacizumab as the first-line therapy. However, only the last two variables were independently associated. Importantly, the objective response rate was 59 % in patients who used bevacizumab as the first-line therapy (67 patients in this analysis).

We analyzed the occurrence of hypertension, the most common side effect of bevacizumab. Hypertension appears to be dose-dependent, and it is currently under investigation as a biomarker for VEGF inhibition efficacy [26, 27]. Bevacizumab-induced hypertension has been reported to be highly associated with improvements in PFS,
OS, and the overall RR [27]. In our study, hypertension grades 2 and 3 were present in 25.8% of patients. Grade 3 hypertension was present in 13.9%, in line with previously reported data [28]. However, we did not identify a significant association between the presence of hypertension and objective response rate. No significant association was seen between outcomes or expression of angiogenesis-related proteins and hypertension.

Although outcome results may vary, the use of bevacizumab therapy has been well established [25, 29]. However, the heterogeneity of results shown in several clinical trials demonstrates an urgent need for biomarkers predicting bevacizumab treatment outcome and toxicity. Different biomarkers such as mutations of BRAF and KRAS [30], microvessel density and VEGF levels [31] have been studied, but no predictive factors have been identified. Biomarkers would allow for the selection of patients most prone to respond to antiangiogenic therapy. In this cohort, the most expressed angiogenesis-related proteins were VEGFR1 and NOTCH1 with a median value of ~65% positive cells.

PlGF is a VEGF homolog and a ligand for VEGFR1 that acts by amplifying the responsiveness of VEGFR1 to VEGF during pathological angiogenesis [32]. NOTCH1 signaling activation has been shown to induce VEGFR1 expression [33] and enhance its responsiveness to PlGF [34]. In line with this, we found significant positive correlations between the expression of VEGFR1 (membrane and cytoplasm) and PlGF, as well as between VEGFR1 (membrane and cytoplasm) and NOTCH1, and NOTCH1 and PlGF. However, although there is a negative NOTCH1 signaling feedback to VEGFR2, resulting in

### Table 2 Association between clinical variables and objective response by RECIST

| Variable                  | Total n | CR + PR n (%) | SD + PD n (%) | p value |
|---------------------------|---------|---------------|---------------|---------|
| Grade                     |         |               |               |         |
| 1 + 2                     | 74      | 42 (57)       | 32 (43)       | 0.01    |
| 3                         | 9       | 1 (11)        | 8 (89)        |         |
| Mucinous histology        | no      | 84            | 46 (55)       | 38 (45) | 0.048 |
|                           | yes     | 10            | 2 (20)        | 8 (80)  |       |
| Liver metastasis          | no      | 31            | 8 (26)        | 23 (74) | 0.001 |
|                           | yes     | 64            | 40 (62)       | 24 (38) |       |
| Peritoneal metastasis     | no      | 79            | 43 (54)       | 36 (46) | 0.09  |
|                           | yes     | 16            | 5 (31)        | 11 (69) |       |
| Chemotherapy              | FOLFIRI | 52            | 25 (48)       | 27 (52) | 0.43  |
|                           | FOLFOX  | 39            | 22 (56)       | 17 (44) |       |
| Hypertension              | no      | 61            | 29 (47)       | 32 (53) | 0.41  |
|                           | yes     | 30            | 17 (57)       | 13 (43) |       |
| Chemo + bevacizumab as 1L | no      | 28            | 9 (36)        | 19 (64) | 0.02  |
|                           | yes     | 67            | 40 (60)       | 27 (40) |       |

RECIST: Response Evaluation Criteria in Solid Tumors; FOLFIRI: infusional 5-fluoro-uracyl plus leucovorin plus irinotecan; FOLFOX: infusional 5-fluoro-uracyl plus leucovorin plus oxaliplatin; CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive Disease (PD). Data are number of patients and numbers in parentheses are percentages. *Chemo: chemotherapy

### Table 3 Multivariate logistic regression analysis showing the variables independently associated with objective response rate (n = 83 patients)

| Covariates             | Odds ratio | CI 95 %    | p value |
|------------------------|------------|------------|---------|
| Chemo + bevacizumab*   | 3.65       | 1.03–12.87 | 0.032   |
| First-line vs. others  | 4.12       | 1.18–14.29 | 0.027   |
| Liver metastasis       |            |            |         |
| yes vs. no             | 9.78       | 0.97–98.98 | 0.059   |
| Histological grade     |            |            |         |
| G1, 2 vs. G3           | 0.47       | 0.03 – 6.18| 0.56    |
| Histology              |            |            |         |
| Mucin-secreting vs. non-mucin-secreting | 0.5 | 0.27 | 0.0072

CI: Confidence interval. *Chemo: chemotherapy

### Table 4 Expression of angiogenesis-related proteins in the total cohort

| Angiogenesis-related protein | n | % of positive cells/core (median) | Range (%) |
|-----------------------------|---|----------------------------------|----------|
| VEGFR1                      | 96| 64.5                             | 1 – 76   |
| VEGFR2                      | 96| 60.4                             | 0 – 86.7 |
| VEGFR3                      | 96| 9.5                              | 0 – 64   |
| PIGF                        | 93| 38.9                             | 0.44 – 83.1|
| DLL4                        | 92| 27                               | 1 – 99   |
| NOTCH1                      | 96| 69                               | 6 – 79   |

### Table 5 Correlations between angiogenesis-related proteins

| Angiogenesis-related proteins | Correlation coefficient | p value |
|------------------------------|-------------------------|---------|
| PIGF and membrane VEGFR1     | 0.50                    | <0.0001 |
| PIGF and cytoplasm VEGFR1    | 0.58                    | <0.0001 |
| PIGF and cytoplasm VEGFR2    | 0.23                    | <0.0001 |
| DLL4 and membrane VEGFR1     | 0.28                    | 0.0243  |
| DLL4 and cytoplasm VEGFR1    | 0.28                    | 0.0056  |
| DLL4 and PIGF                | 0.24                    | 0.0172  |
| DLL4 and NOTCH1              | 0.25                    | 0.0161  |
| NOTCH1 and membrane VEGFR1   | 0.56                    | <0.0001 |
| NOTCH1 and cytoplasm VEGFR1  | 0.34                    | <0.0001 |
| NOTCH1 and PIGF              | 0.27                    | 0.0072  |
decreased endothelial cell proliferation in response to VEGF [35], there was no significant correlation between the expression of NOTCH1 or DLL4 and VEGFR2. While bevacizumab treatment has been associated with increased levels of PlGF [36], its value as a biomarker remains largely unknown. Instead of contributing to tumor escape and resistance, as has been suggested, increased PlGF expression might only be a host response elicited by angiogenic therapies [37] since it has been associated with better outcomes in glioblastoma [38].

We also analyzed the association of angiogenesis-related protein expressions with clinical and pathological characteristics. In tumors or plasma, VEGFR1 is a strong biomarker candidate to predict response to bevacizumab [39]. The median expression of VEGFR1 was twice that of VEGFR2 in our cohort, and higher expression of membrane VEGFR1 was associated with lung metastasis. In the MAX III trial (testing the combination of capecitabine, bevacizumab and mitomycin), the authors observed an association between low VEGFR1 expression by immunohistochemistry on tumors and improved OS [39].

VEGFR3 is a major inducer of lymphangiogenic signaling, but its expression has been associated with the presence of hematogenous metastasis [40] and poor OS [41]. In our cohort, while higher expression of membrane and cytoplasmic VEGFR3 was associated with lung metastasis, lower expression was associated with liver metastasis. YILDIZ et al. (2010) evaluated the expression of VEGFR3 by immunohistochemistry in tumor samples from metastatic colorectal cancer patients treated with chemotherapy and bevacizumab and observed positive expression in 20 % of cases. The authors did not identify any association with efficacy outcomes [42].

Increased NOTCH1 expression was associated with lymph node metastasis, which is in line with previously reported data [43, 44].

PFS was not significantly associated with any of the angiogenesis-related proteins. We saw a trend toward

### Table 6

| Characteristic | p  |
|---------------|----|
| Membrane      | Lung metastasis | 0.002 |
| Cytoplasm     | Stage I and II  | 0.03  |
| VEGF2         | Cytoplasm       | 0.03  |
| Cytoplasm     | Lung metastasis | 0.003 |
| PlGF          | Stages I and II | 0.04  |
| NOTCH1        | Metastasis to regional lymph nodes (N1 or N2) | 0.04  |

### Table 7

| Covariates                | HR    | CI 95 %      | p    |
|---------------------------|-------|--------------|------|
| Liver metastasis (yes vs. no) | 1.93  | 1.09 – 3.44  | 0.024|
| Histological grade (1 + 2 vs. 3) | 2.79  | 1.16 – 6.68  | 0.021|
| ECOG (0 + 1 vs. 2 + 3)      | 20.50 | 3.08 – 136.11| 0.002|
| NOTCH1                     | 2.01  | 1.07 – 3.77  | 0.029|

HR: Hazard ratio; ECOG: Eastern Cooperative Oncology Group performance status score; CI: Confidence interval

Fig. 4 The progression-free survival curve for NOTCH1 expression, p = 0.06 (a), and the overall survival for NOTCH1, p = 0.01 (b). Low expression: < median expression value vs. high expression: ≥ median expression value. The survival curves were calculated using the Kaplan-Meier method, and the log-rank test was used for comparison.
longer PFS in patients whose tumors bore lower expression of NOTCH1, most likely because NOTCH1 expression might be involved in tumor resistance to bevacizumab. Angiogenesis induced by DLL4-NOTCH1 signaling generates large vessels that increase tumor blood supply and diminish sensitivity to bevacizumab [16]. Besides, lower expression of NOTCH1 was significantly associated with better OS. NOTCH1 activation induces VEGFR3 [5], and it has already been associated with poor survival [43]. In multivariate analysis, the only factors that were independently associated with PFS were histological grade and metastasis resection. For OS, NOTCH1 remained an independent variable, confirming the reported association between overactivated NOTCH1 signaling and poor survival in CRC [43]. CHU et al. described that, among 1003 tumor samples from early stage resected colorectal cancer, 52.1 % of cases were positive for NOTCH1 and 33.4 % for NOTCH2 by immunohistochemistry. Patients bearing NOTCH1 positive tumors had worse OS (38 months vs 66 months for NOTCH1 negative cases). The opposite results were observed in association with NOTCH2 expression, where low NOTCH2 was associated with worse OS [45]. Similarly, we also found that NOTCH1 hyperexpression is associated with reduced OS, however differently from the studies by CHU et al. (2011) [46, 47], our cohort is composed solely of metastatic colorectal cancer patients treated with chemotherapy plus bevacizumab. Although, we cannot draw conclusions on the predictive capacity of NOTCH1, we believe it is definitely prognostic, and, to our knowledge, this is the first published report showing this association in this population.

In summary, the results of this retrospective study are similar to the outcomes observed in large clinical trials confirming the effectiveness of bevacizumab in common daily practice. The expression profile of angiogenesis-related proteins and their association with clinicopathological characteristics and outcomes were described, building on the current understanding of the role of these proteins in the setting of chemotherapy in addition to bevacizumab therapy. Our results suggest that NOTCH1 might serve as a prognostic marker for colorectal cancer in the metastatic setting.

**Conclusion**

We evaluated the expression of proteins involved with angiogenesis in colorectal tumor samples from patients receiving bevacizumab in conjunction with chemotherapy. High expression levels of VEGFR1 and VEGFR3 were associated with a higher rate of lung metastasis. VEGFR3 expression was also associated with liver metastasis. NOTCH1 expression was associated with an increased risk of lymph node metastasis and a worse overall survival.

**Additional files**

**Additional file 1: Table S1.** Demographic and clinical characteristics of patients receiving chemotherapy plus bevacizumab as first-line treatment (N = 73).

| Characteristics | Count | Percentage |
|-----------------|-------|------------|
| Age (years)     |       |            |
| Sex             |       |            |
| Race            |       |            |
| Tumor Stage     |       |            |
| Metastasis      |       |            |

Table depicts overall response rate (ORR), PFS (progression free survival) and overall survival (OS) of patients treated with chemotherapy plus bevacizumab in first-line in comparison to second-line. (DOCX 81 kb)

**Abbreviations**

BRAF: v-RAF murine sarcoma viral oncogene homolog B; CI: Confidence interval; CRC: Colorectal cancer; DLL4: Delta-like ligand; ECOG: Eastern Clinical Oncology Group; FOLFIRI: Folinic acid + 5-fluorouracil + irinotecan; FOLFOX: Folinic acid + 5-fluorouracil + oxaliplatin; HR: Hazard ratio; KRAS: Kirsten rat sarcoma viral oncogene homolog; NOS: Not otherwise specified; NOTCH1: Neurogenic locus notch homolog protein 1; OS: Overall survival; PFS: Progression free survival; PlGF: Placental growth factor; RECIST: Response evaluation criteria in solid tumors; TMA: Tissue microarray; TNM: Tumor, node and metastasis; VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

TFJP: was responsible for the collection and the quality of clinical data, had full access to all data, and performed the data analysis. CCCL: was the leader and designed the study, had full access to all data, performed the data analysis and drafted all the versions of the manuscript. MDB: was the project leader and designed the study, had full access to all data, performed the data analysis and drafted all the versions of the manuscript. MAB: was the project leader, helped to design the study, made a critical review and proofread of the document. AD, AB: were responsible for the statistical data analysis and drafted all the versions of the manuscript. BMR: was the leader pathologist, helped to design the study, made a critical review and proofread of the document. VHF, RAM: were responsible for the collection and the quality of clinical data and provided comments on the drafts. All the authors: read and approved the final version of the manuscript.

**Authors’ information**

Not applicable.

**Availability of supporting data**

Not applicable.

**Acknowledgements**

The authors take full responsibility for the content of this publication. We thank the Expertix Medical Communications, funded by Produtos Roche Químicos e Farmacêuticos SA for providing writing and editing support. Produtos Roche Químicos e Farmacêuticos SA did not influence the content of the report, nor did the authors receive any financial compensation for authoring the report.

**Funding**

This study was funded by the FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo - number 2010/07858-2).

**Author details**

1Department of Medical Oncology, A. C. Camargo Cancer Center, São Paulo, Brazil. 2Department of Pathology, A. C. Camargo Cancer Center, São Paulo, Brazil. 3Department of Statistics, Centro Internacional de Pesquisa e Ensino - Fundação Antônio Prudente, São Paulo, Brazil. 4PhD/MSc Program, Hospital Sírio-Libanês, São Paulo, Brazil. 5Department of Clinical Oncology, 1st Subsolo, Edifício Hilda Jacob R. Prof. Antônio Prudente, 211, São Paulo ZC 01509-900, Brazil.
References

1. Ferlay JS, Zikov M, Eriuk R, Eser S, Mathets C, Rebello M, et al. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 08/04/2014.

2. Van Cutsem E, Oliveira J, Group EGW. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2009;20 Suppl 6:41–6.

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):10–29.

4. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–49.

5. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer. 2011;11:338–51.

6. Sumam S, Das TP, Ankem MK, Damodaran C. Targeting Notch Signaling in Colorectal Cancer. Curr Colorectal Cancer Rep. 2014;10(4):411–6.

7. Li JL, Sanson RC, Oon CE, Turley H, Leek R, Sheldon H, et al. DLL4-Notch signaling mediates tumor radioresistance to anti-VEGF therapy in vivo. Cancer Res. 2011;71(18):6073–83.

8. Temraz S, Mukhejdi D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer. Where to fit the target. World journal of gastroenterology: WJG. 2014;20(8):1993–2004.

9. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65(3):671–80.

10. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line treatment for metastatic colorectal cancer: a randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(12):1939–9.

11. Hurwitz H, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin as an active regimen for first-line metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(35):5022–8.

12. Giannonio BJ, Catalano PJ, Meprol NJ, D’Oweyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. Journal of oncology : official journal of the American Society of Clinical Oncology. 2007;25(12):1539–44.

13. Kabbinavar F, Hurwitz H, Fehrenbacher L, Meprol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil plus folinic acid (FU/FA) to FU/FA alone in patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(10):1650–5.

14. Pitoliano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, et al. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer. 2008;7(1):155–9.

15. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18474) : a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37.

16. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(20):6371–5.

17. Zhang Y, Li B, Ji ZZ, Zheng PS. Notch1 deficiency results in decreased DLL4-Notch pathway activity and improved tumour growth in colon cancer. WJG. 2014;20(8):1993.

18. Jubb AM, Hurwitz H, Bai W, Holmgren EB, Tobin P, Guerrero AS, et al. Impact of vascular endothelial growth factor receptor-2 expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(21):3497–503.

19. Carmeliet P, Moons L, Luttun A, Vincente V, Compérille V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575–83.

20. Oztür H, Wu J, Wang X, Kutuzov J. Notch1 deficiency results in decreased inflammation during wound healing and regulates vascular endothelial growth factor receptor-1 and inflammatory cytokine expression in macrophages. J Immunol. 2011;187(7):3663–73.

21. Funahashi Y, Shiwab S, Vorontchikina M, Sharma A, Ottuz HH, Kutuzov J. Notch regulates the angiogenic response via induction of VEGFR-1. J Angiogenes Res. 2010;2;1(3).

22. Taylor KL, Henderson AM, Hughes CC. Notch activation during endothelial cell network formation in vitro targets the basic HhL transcription factor HESR-1 and downregulates VEGFR-2/ND expression. Microvasc Res. 2002;64(3):372–83.

23. Willett CG, Duda DG, Di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficiency, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multicentric phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(18):3020–6.

24. Bagley RG, Ben Y, Webster W, Yao M, Kurtzberg L, Princen J, et al. Placental growth factor upregulation is a host response to antiangiogenic therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17(5):1976–88.

25. Batchelor TT, Duda DG, Di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(17):2817–23.

26. Lambrechts D, Lenz HJ, de Haas S, Carmellet P, Scherer S. Markers for response in the antiangiogenic agent bevacizumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(9):1219–30.
40. Jayasinghe C, Simiantonaki N, Michel-Schmidt R, Kirkpatrick CJ. Endothelial VEGFR-3 expression in colorectal carcinomas is associated with hematogenous metastasis. Oncol Rep. 2009;22(5):1093–100.

41. Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M, Filho AL. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics. 2013;10(2):55–67.

42. Chu D, Li Y, Wang W, Zhao Q, Li J, Lu Y, et al. High level of Notch1 protein is associated with poor overall survival in colorectal cancer. Ann Surg Oncol. 2010;17(5):1337–42.

43. Park HS, Jung CK, Lee SH, Chae BJ, Lim DJ, Park WC, et al. Notch1 receptor as a marker of lymph node metastases in papillary thyroid cancer. Cancer Sci. 2012;103(2):305–9.

44. Yildiz R, Corkun LJ, Baglan T, Buyukberber S, Uner A, Erdem D, et al. The relation between endoglin (CD105), thrombospondin-1 and VEGFR-3 and treatment results in metastatic colorectal cancer patients treated with Bevacizumab combination therapy. Ann Oncol. 2010;21 Suppl 8:A685. Presented at Colorectal Cancer Symposium of the 35th ESMO Congress Milan, Italy 8–12 October 2010.

45. Shawber CJ, Funahashi Y, Francisco E, Vorontchkikhina M, Kitamura Y, Stowell SA, et al. Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J Clin Invest. 2007;117(11):3369–82.

46. Chu D, Zhang Z, Zhou Y, Wang W, Li Y, Zhang H, et al. Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Ann Oncol. 2011;22:2440–7.

47. Chu D, Zhou Y, Zhang Z, Li Y, Zheng J, Zhang H, et al. Notch1 expression, which is related to p65 Status, is an independent predictor of prognosis in colorectal cancer. Clin Cancer Res. 2011;17(17):5686–94.